Asensus Surgical Overview
Valuation check: ASXC's ROE is 739.82%, above the Healthcare sector average of 22.01%.
Get informed when a big investor buys or sells
+ Follow739.82%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Asensus Surgical (ASXC) currently reports a ROE of 739.82%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore Asensus Surgical's ROE history and peer comparisons.
Asensus Surgical's ROE of 739.82% is higher than the Healthcare sector average of 22.01%. That is roughly 3261.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Asensus Surgical's current 739.82% should be judged against Healthcare norms (sector average: 22.01%) and against ASXC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 739.82%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Asensus Surgical, and consider following ASXC for alerts when major investors trade the stock.
Asensus Surgical is classified in the Healthcare sector. On ROE, it currently shows 739.82% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ASXC with unrelated industries.
